The Eye Flu (Conjunctivitis) market is estimated to be valued at US$ 4.54 Bn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Eye flu, also known as conjunctivitis, is a common eye condition caused by bacterial or viral infection or allergies. It is highly contagious and causes redness, inflammation, tearing, discharge and itching of the eyes. The main symptoms include pink eye, redness of the eyes, discharge and itching in and around the eyes. Eye flu causes visual disturbances and impairment of vision if left untreated. Products available in the market for treatment of eye flu include eye drops, ointments, gels and medications. Eye drops are the most widely used products for treatment of eye flu as they are convenient to use and offer quick relief from symptoms.
Market Dynamics:
The Eye Flu Market Size is driven by growing prevalence of eye infections across the globe. According to the Centers for Disease Control and Prevention (CDC), viral conjunctivitis is one of the most common causes of infectious disease witnessed globally, affecting 1-2 million people in the United States annually. The increasing awareness about eye health and adoption of hygienic practices to avoid contracting infections is also fueling the demand for eye flu treatment products. Moreover, rising healthcare expenditure in emerging economies provide significant growth opportunities in the market. On the other hand, availability of generic drugs and self-medication practices pose a threat to established players in the eye flu treatment market.
SWOT Analysis
Strength: Eye flu (conjunctivitis) market has witnessed strong growth over the past few years owing to rising adoption of eye care products and availability of effective treatment therapies. The established supply chain and distribution network of key players ensures strong supply of quality eye flu treatment medications. Furthermore, extensive research and development activities have led to development of innovative drugs with improved efficacy.
Weakness: High treatment cost associated with chronic and severe cases of eye flu may restrict market growth to some extent. Adoption of alternative treatment methods such as homeopathy can also hinders the revenue of allopathic eye flu drugs manufacturers.
Opportunity: Growing elderly population prone to eye disorders and infections creates growth opportunity for eye flu market. Furthermore, rapid expansion of e-commerce platforms has facilitated easy accessibility of eye care products, thus presenting an opportunity for market expansion.
Threats: Patent expiry of blockbuster drugs increases competition among local and generic drug manufacturers. Stringent regulations regarding clinical trials and approval of new drugs in developed markets may also challenges further innovations.
Key Takeaways:
The global eye flu (conjunctivitis) market is expected to witness high growth, exhibiting CAGR of 8.0% over the forecast period, due to increasing prevalence of eye infections and disorders related to growing pollution levels. The market size is estimated to reach US$ 7.76 Bn by 2030 from US$ 4.54 Bn in 2023.
Regional analysis The North America region currently dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to factors such rising healthcare expenditure, availability of advanced products, rising bacterial and viral infections in the region. Asia Pacific eye flu market is projected demonstrate fastest growth owing to expanding patient pool, improving access to healthcare facilities and rising medical tourism in the region.
Key players operating in the eye flu (conjunctivitis) market are Novartis, Allergan, Bausch Health, Santen Pharmaceutical, Johnson & Johnson, Alembic Pharmaceuticals, Akorn Pharmaceuticals, Alcon, Pfizer, Valeant Pharmaceuticals, Merck & Co., Similasan Corporation, Sun Pharmaceutical Industries, Prestige Consumer Healthcare, Lupin Pharmaceuticals, Alembic Pharmaceuticals, Aurolab, Intas Pharmaceuticals, Sun Pharma, Cipla.
Read Our More Blogs : https://www.pressreleasebulletin.com/eye-flu-conjunctivitis-market-analysis-growth-forecast-outlook-2023-2030/
Sign in to leave a comment.